The purpose of this study is
To evaluate the efficacy of association of Erythropoetin (Neorecormon) and ATRA in patients with low risk myelodysplastic syndromes
To evaluate the tolerance of this treatment

Start Date01 Oct 2004

Sponsor / Collaborator

Groupe Francophone des Myélodysplasies

100 Clinical Results associated with Epoetin/Atra

100 Translational Medicine associated with Epoetin/Atra

100 Patents (Medical) associated with Epoetin/Atra

Literatures (Medical) associated with Epoetin/Atra

25 Jan 2021·Nephrology Dialysis TransplantationQ2 · MEDICINE

Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease

Q2 · MEDICINE

Article

Author: Garofalo, Carlo ; Del Vecchio, Lucia ; De Nicola, Luca ; Chiodini, Paolo ; Locatelli, Francesco ; Minutolo, Roberto ; Aucella, Filippo ; Scaglione, Francesco

AbstractBackgroundDespite the widespread use of erythropoiesis-stimulating agents (ESAs) to treat anaemia, the risk of adverse outcomes associated with the use of different types of ESAs in non-dialysis chronic kidney disease (CKD) is poorly investigated.MethodsFrom a pooled cohort of four observational studies, we selected CKD patients receiving short-acting (epoetin α/β; n = 299) or long-acting ESAs (darbepoetin and methoxy polyethylene glycol-epoetin β; n = 403). The primary composite endpoint was end-stage kidney disease (ESKD; dialysis or transplantation) or all-cause death. Multivariable Cox models were used to estimate the relative risk of the primary endpoint between short- and long-acting ESA users.ResultsDuring follow-up [median 3.6 years (interquartile range 2.1–6.3)], the primary endpoint was registered in 401 patients [166 (72%) in the short-acting ESA group and 235 (58%) in the long-acting ESA group]. In the highest tertile of short-acting ESA dose, the adjusted risk of primary endpoint was 2-fold higher {hazard ratio [HR] 2.07 [95% confidence interval (CI) 1.37–3.12]} than in the lowest tertile, whereas it did not change across tertiles of dose for long-acting ESA patients. Furthermore, the comparison of ESA type in each tertile of ESA dose disclosed a significant difference only in the highest tertile, where the risk of the primary endpoint was significantly higher in patients receiving short-acting ESAs [HR 1.56 (95% CI 1.09–2.24); P = 0.016]. Results were confirmed when ESA dose was analysed as continuous variable with a significant difference in the primary endpoint between short- and long-acting ESAs for doses >105 IU/kg/week.ConclusionsAmong non-dialysis CKD patients, the use of a short-acting ESA may be associated with an increased risk of ESKD or death versus long-acting ESAs when higher ESA doses are prescribed.

01 Jun 2019·Journal of the American Society of NephrologyQ1 · MEDICINE

Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis

Q1 · MEDICINE

Article

Author: Sakaguchi, Yusuke ; Masakane, Ikuto ; Wada, Atsushi ; Hamano, Takayuki

Significance StatementAlthough both short-acting and long-acting erythropoietin-stimulating agents (ESAs) are used to treat anemia in patients undergoing hemodialysis, the relative effects on survival of these ESA types are unknown. In this nationwide, registry-based cohort study enrolling 194,698 patients on hemodialysis, the authors found that long-acting ESA users showed a 13% higher rate of death than short-acting ESA users (P<0.001) during the 2-year follow-up period. The difference in risk was pronounced among patients receiving high doses of ESA, for whom the adjusted 2-year number needed to harm for death was 30.8. Survival of long-acting ESA users who achieved more optimal hemoglobin levels was inferior to that of short-acting ESA users. Among patients on hemodialysis, long-acting ESA use might be associated with an increased rate of death compared with short-acting ESA use.BackgroundDespite the widespread use of erythropoietin-stimulating agents (ESAs) to treat anemia in patients undergoing hemodialysis, the relative mortality risks associated with use of different types of ESAs are unknown.MethodsTo compare the mortality risk associated with use of short-acting ESAs versus long-acting ESAs, we conducted a nationwide cohort study of 194,698 hemodialysis patients in Japan who received either a short-acting (epoetin α/β or epoetin κ) or a long-acting (darbepoetin or epoetin β pegol) ESA. Study outcomes were 2-year all-cause and cause-specific mortality. In addition to Cox proportional hazards models, we performed an instrumental variable analysis in which facility-level long-acting ESA prescription rates were taken as the instrumental variable.ResultsDuring the 2-year follow-up period, 31,557 deaths occurred. In a multivariable Cox model, long-acting ESA users had a 13% higher rate of deaths compared with short-acting ESA users, a significant difference (P<0.001). Similar results were obtained in other analyses. This difference in risk was pronounced among patients receiving high doses of ESA (for whom the adjusted 2-year number needed to harm for death was 30.8). Long-acting ESA use was associated with an increased rate of death from cardiovascular diseases, infection, and malignancies. In the instrumental variable analysis, long-acting ESA users remained at a significantly higher risk of death. Compared with anemic (hemoglobin 9.0–9.9 g/dl) short-acting ESA users, long-acting ESA users who achieved more optimal hemoglobin levels (10.0–10.9 g/dl) showed a higher mortality rate.ConclusionsAmong patients undergoing hemodialysis, use of long-acting ESAs might be associated with a higher risk of death than use of short-acting ESAs.

01 Nov 2013·Drug Testing and AnalysisQ2 · MEDICINE

Desialylation improves the detection of recombinant erythropoietins in urine samples analyzed by SDS‐PAGE

Q2 · MEDICINE

Article

Author: Desharnais, Philippe ; Ayotte, Christiane ; Naud, Jean‐François

Recombinant erythropoietin (rhEPO) has been misused for over two decades by athletes, mainly but not only in endurance sports. A direct rhEPO detection method in urine by isoelectric focusing (IEF) was introduced in 2000, but the emergence of third‐generation erythropoiesis‐stimulating agents and so‐called biosimilar rhEPOs, together with the sensitivity of human endogenous EPO (huEPO) pattern to enzymatic activities and its modification following short strenuous exercise, prompted the development of a complementary test based on SDS‐PAGE analysis. While Mircera and NESP are easily detected with the existing IEF and SDS‐PAGE methods, some samples containing both epoetin‐α/β and huEPO present profiles that are still difficult to interpret. As doping practices have moved to micro‐dosing, these mixed patterns are more frequently observed. We investigated the impact of enzymatic desialylation on the urinary and serum EPO profiles obtained by SDS‐PAGE with the aim of improving the separation of the bands in these mixed EPO populations. We observed that the removal with neuraminidase of the sialic acid moieties from the different EPOs studied reduced their apparent molecular weight (MW) and increased the migration distance between huEPO and rhEPO centroids, therefore eliminating the size overlaps between them and improving the detection of rhEPO. Copyright © 2013 John Wiley & Sons, Ltd.

100 Deals associated with Epoetin/Atra

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Anemia	Phase 2	FR	Groupe Francophone des Myélodysplasies	31 Oct 2004
Myelodysplastic Syndromes	Phase 2	FR	Groupe Francophone des Myélodysplasies	01 Oct 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Epoetin/Atra

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation